AF risk is real in OM3 use. Counsel/Discuss with your patients if deciding to use an OM3.
Remember though, in placebo, AF occurs too. Thus, recognize the background risk of AF regardless of OM3. Of course, decide whether EPA or EPA/DHA is beneficial or not 😉
In an EPA/DHA mixed formulation in STRENGTH, (REDUCEIT is EPA-only).
EPA had 443% increase, DHA 68% increase.
While "no harm" is reported, this does not answer whether DHA "blunted" EPA benefit. 8/
#ACC21
Disclosure: Site investigator/co-author of EVAPORATE, oral abstract presented at ACC21 05/17 on Intermountain data looking at higher DHA level affect on EPA benefits.
9/
This STREGNTH sub-study looks at achieved levels in a mixed EPA/DHA formulation, we looked at whether circulating levels of EPA and DHA impact one another's effect on MACE. No spoilers, just read our title ;)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
💊nutraceuticals ubiquitous and “assumed” by many pts to be heart healthy.
💊💰💸industry
💊 SPORT ➡️ compared to rosuva and placebo, do they impact biomarkers? jacc.org/doi/abs/10.101… @kewatson@ErinMichos@ljlaffin 1/
N=199, randomized single blind
💊 lipid, hsCRP, CMP. Baseline and at 28 days.
💊 1° risk, age 40-75, LDL-C 70-189, borderline to upper intermediate risk (5-20%, estimated 10 yr event)
💊 1° endpt: %LDL-C change vs rosuva
💊2° endpt: biomarkers vs rosuva; vs placebo #aha22 2/
💊 most were at least 7.5% 10 year risk
💊 nice representation of 💃🏽
💊 LDL-C >100 (~125); hsCRP <2.0
🐟interesting drop out rate/protocol deviation, covid era?
🐟LDL-C baseline, similar to reduce it
🐟EPA median 46 ug/mL, higher than reduce it (26), lower than Jelis (96).
🐟hsCRP ~0.40 2/ #aha22
Throwing dollars at “health”doesn’t = improved health. This is staggering. We need to change what and how we deliver #Healthcare and where the $$ are spent #aha22